Universitats klinikum Marburg
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walter, Benjamin
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
10/24
10/24
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
ARCHES, NCT05041283: Impact of Artificial Intelligence-based Patient Reinforcement on Quality of Colonoscopy

Recruiting
N/A
258
Europe
Chatbot, Phone call
University of Ulm
Bowel Preparation
02/22
02/22
HADRIAN, NCT05517369: Impact of Hybrid-ESD+ and LiftUp® on the en Bloc/R0 Rate in Colorectal Adenomas Between 2 and 3 cm

Withdrawn
N/A
60
Europe
Hybrid ESD+
Wuerzburg University Hospital, Waid City Hospital, Zurich, University Hospital Ulm, Rems-Murr-Klinikum Winnenden, Insel Gruppe AG, University Hospital Bern, Klinikum Ludwigsburg, Mathilden Hospital Herford, St. Franziskus Hospital Münster, Agaplesion Kliniken Kassel, Ovesco Endoscopy AG
Colorectal Adenoma
04/24
10/24
Schneider, Ruth
Generate-Boost, NCT03993262: Trial to Evaluate Efficacy and Safety of Bortezomib in Patients with Severe Autoimmune Encephalitis

Recruiting
2
50
Europe
Bortezomib, Placebo, isotonic NaCl solution
Jena University Hospital, Federal Ministry of Education and Reserach (BMBF)
Autoimmune Encephalitis
11/25
04/26
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
OPAL, NCT05287620: Objective, Passive Assessment of LRRK2 Carriers

Completed
N/A
10
US
Emerald device
University of Rochester, Emerald Innovations, Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease
05/24
05/24
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33

Download Options